Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuation of Gefitinib Beyond Progression in EGFR+ NSCLC
NCT03399669Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Feb 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03399669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03399669.